GLP-1 drug plus hormone IUD for early endometrial cancer in obesity
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests if adding a GLP-1 weight-loss drug to a hormone-releasing IUD can help treat very early endometrial cancer or a precancerous condition in women with obesity. The goal is to see if this combination is effective without surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have been diagnosed in the last 4 months with grade 1 endometrial cancer or a precancer called EIN (endometrioid intraepithelial neoplasia).
- Your body mass index (BMI) is 30 or higher (classed as obese).
- You either want to preserve your fertility or have other health problems that make surgery risky.
- You have not already started a GLP-1 drug more than 14 days ago, and you have not had a hormone IUD placed more than 45 days before joining.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a weight-loss drug (tirzepatide) combined with a hormone-releasing IUD to treat certain early-stage uterine conditions without surgery. It may help women who are overweight or obese and want to avoid hysterectomy.
This study tests whether a three-month program that includes weight-loss medications and hormone therapy before surgery is better than surgery alone for women with early-stage endometrial cancer and severe obesity. The goal is to see if this approach improves surgical outcomes and overall health.
This trial tests combining a weight-loss medication (mazdutide) with a hormone-releasing intrauterine device (LNG-IUS) to treat early-stage uterine cancer or precancerous changes while preserving fertility. It aims to help patients who are overweight or obese and wish to avoid hysterectomy.
This study tests whether a diabetes medication called tirzepatide, combined with a hormone-releasing device, can help shrink or stop early-stage endometrial cancer (cancer of the uterine lining) in patients who are overweight and either cannot have surgery right away or prefer to delay it. The goal is to see if this approach can be an alternative to immediate surgery.
This study looks at whether a hormone-releasing IUD (LNG-IUS) can treat early-stage endometrial cancer or very early abnormal cell growth while helping you keep the option for future pregnancy. It aims to see how well the treatment works and how it affects fertility-related outcomes.
This trial studies a weight-management approach plus a progesterone-releasing IUD (LNG-IUS) and megestrol to treat endometrial atypical hyperplasia, a high-risk precancer of the uterine lining. It may help shrink or control the abnormal cells while supporting fertility or keeping the uterus.
Hear when a new Endometrioid Endometrial Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.